All News

The latest stage of Europe’s attempt to update its clinical trials rules offered a mildly distressing spectacle of the intrusion of politics into policy, writes Peter O’ Donnell.

Getting patients to take their medicine on spec and on time is the challenge that never goes away-it's the deadweight baggage accompanying every industry innovation since the arrival of aspirin a century ago.

S

PharmExec sat down with Colleen A. McHorney, PhD, former Senior Scientist at Merck’s U.S. Outcomes Research to review her long record of scientific research on adherence in advance of her retirement last month.

Pharmaceutical Executive offers a unique platform to engage with high level executives at pharmaceutical companies across multiple platforms

Clark Herman Biography

New approaches for conducting clinical trials and developing therapies that actually prevent and cure disease are key to the future of effective drug therapy, according to Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER).

I’m sure you’ve heard already - Internet geriatric Yahoo just bought six-year old Tumblr for $1.1 billion. The deal, likely to complete in the second half of this year, is almost all cash - reportedly almost all the cash Yahoo had in hand at the close of the first quarter.

For CEOs who have spent long years and countless funds building a solid pharmaceutical brand and life-changing drugs, discovering defamatory remarks about your company online can come as quite a shock.

If you are an Rx regional sales director or a product marketing manager, I have a somewhat provocative question for you: How exactly are you planning your 2014 Medicaid strategy?

The UK’s Royal Pharmaceutical Society has joined forces with a number of other organizations, including the Association of the British Pharmaceutical Industry (ABPI), to issue new guidance on medicines optimization. Sir Bruce Keogh, Medical Director of NHS England, says it could be revolutionary.

US-based Bayer Healthcare Pharmaceuticals, as its executives were quick to point out, has now received three new approvals for cancer indications in the last eight months

The global market for biosimilar drugs has been forecasted to be worth $2.445 billion this year, according to a new report by British market research specialist Visiongain

The problem we see with the polarity of views is that both sides seem to be cranking up the extrapolation machine and use single studies/data points to draw broad conclusions to gin up opinions about ACA’s success or lack thereof.

One of the things that we’re hearing a lot about right now is big data. We’re told that we’re entering an era of big data that will come to transform business and government services alike.

At a time when Big Pharma is struggling with new business models geared to the demands of a changing marketplace, the Medicines Patent Pool (MPP) is offering a way forward through voluntary licensing and patent deals that it insists will deliver what the drug majors say they want: more innovation; better market access; and the opportunity to demonstrate measurable improvements in public health. Is the MPP, as founding chair Phillipe Douste-Blazy claims, that “new business model for the future?”

It’s exciting times for patents in Europe. Not everyone’s excitement is pleasurable, but there’s certainly plenty going on, writes Reflector, Pharm Exec‘s EU correspondent.

During the Rutgers Business School’s annual healthcare symposium, an FDA official encouraged industry to put its drugs on the reviewing table and be prepared for good news.

Pharma should have a head start in the content marketing race, but familiar fears are holding it back, writes Peter Houston.

Pharmaceutical Research and Manufacturers of America (PhRMA) International Vice-President Jay Taylor has expressed the organization’s concerns over the Office of the United States Trade Representative’s (USTR) 2013 Special 301 Report.

S

A night of comedy in support of a chronic disease.

Just about every federal program and affected interest group is pressing for relief from the 8% across-the-board cuts in funding imposed by the budget sequestration mandate. Recent fast action on Capitol Hill to curb personnel furloughs of air traffic controllers by the Federal Aviation Administration, though, has spurred lobbying for similar treatment across many fronts.

The new National Patient-Centered Clinical Research Network funded by the Patient-Centered Outcomes Research Institute (PCORI) aims to provide patients and clinicians with useful information on treatment options and outcomes

In a recent survey by Ipsos Healthcare, oncologists from the US, China, Brazil, and the EU Big 5, expressed strong dissatisfaction with the direction and pace of local healthcare initiatives.

The current UK measles outbreak reminds us that, as far as healthcare communication is concerned, the voice of the people is not necessarily the voice of God, writes Reflector.

You’d be forgiven for missing it with the vast array of new agencies and the policy documents, guidance, consultations and ‘engagement’ activity they’re doing on in the ‘new’ NHS in England, but on the 4th April NHS England (formerly the NHS Commissioning Board) set out 15 commissioning policies in 250 pages.

The Food and Drug Administration has come down on the side of reducing abuse of opoid medications, over encouraging wider availability of low-cost painkiller meds.

Forget digital differentiation and innovation. You need to be focusing on cross-channel ‘fusion’, writes Peter Houston.

The Obama administration’s budget plan for fiscal year 2014 apparently assumes that the pharmaceutical industry can support Medicare and other health programs through changes in drug coverage and payments.